BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a world biotechnology firm,in the present day introduced that the Firm will take part in two upcoming investor conferences:
- The Guggenheim Oncology Convention 2023 on Wednesday, February 8, 2023 at 9:35 a.m. ET; and
- The SVB Securities International Biopharma Convention on Wednesday, February 15, 2023 at 1:40 p.m. ET.
Reside webcasts of those occasions will be accessed from the buyers part of BeiGene’s web site at httppercent3Apercent2Fpercent2Fir.beigene.com and archived replays might be obtainable for 90 days following the occasions.
BeiGene is a world biotechnology firm that’s growing and commercializing revolutionary and reasonably priced oncology medicines to enhance therapy outcomes and entry for a lot extra sufferers worldwide. With a broad portfolio, we’re expediting improvement of our various pipeline of novel therapeutics by our inside capabilities and collaborations. We’re dedicated to radically enhancing entry to medicines for a lot extra sufferers who want them. Our rising international group of greater than 9,000 colleagues spans 5 continents, with administrative places of work in Cambridge, U.S., & Basel, Switzerland & Beijing, China. To study extra about BeiGene, please go to www.beigene.com and comply with us on Twitter at @BeiGeneGlobal.
View supply model on businesswire.com: https://www.businesswire.com/information/residence/20230201005204/en/